U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H23F3O5S
Molecular Weight 444.465
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SELADELPAR

SMILES

CCO[C@H](COC1=CC=C(C=C1)C(F)(F)F)CSC2=CC=C(OCC(O)=O)C(C)=C2

InChI

InChIKey=JWHYSEDOYMYMNM-QGZVFWFLSA-N
InChI=1S/C21H23F3O5S/c1-3-27-17(11-28-16-6-4-15(5-7-16)21(22,23)24)13-30-18-8-9-19(14(2)10-18)29-12-20(25)26/h4-10,17H,3,11-13H2,1-2H3,(H,25,26)/t17-/m1/s1

HIDE SMILES / InChI
Molecular Formula C21H23F3O5S
Molecular Weight 444.465
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

MBX-8025 (Seladelpar) is an agonist of peroxisome proliferator-activated receptor delta. MBX-8025 improves insulin sensitivity and reverses dyslipidemia and hepatic storage of lipotoxic lipids to improve nonalcoholic steatohepatitis pathology in atherogenic diet-fed obese diabetic mice. MBX-8025 improves lipoprotein subfractions associated with atherogenic dyslipidemia. CymaBay Therapeutics is developing MBX-8025 for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis and nonalcoholic steatohepatitis.

Originator

Approval Year

2024
711
Targets

Targets

Primary TargetPharmacologyConditionPotency
Peroxisome proliferator-activated receptor delta
30
Target ID: Q03181|||Q9BUD4
Gene ID: 5467.0
Gene Symbol: PPARD
Target Organism: Homo sapiens (Human)
Agonist
2752
 2.0 nM [EC50]
PubMed

PubMed

TitleDatePubMed
MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin.
2011 Sep

Sample Use Guides

In Vivo Use Guide
Phase 2 study to evaluate the safety and efficacy of MBX-8025 2 mg, 5 mg, and 10 mg over 52 weeks of treatment
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:10:52 GMT 2025
Edited
by admin
on Mon Mar 31 18:10:52 GMT 2025
Record UNII
7C00L34NB9
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
(+)-MBX-8025
Preferred Name English
SELADELPAR
INN   WHO-DD  
INN  
Official Name English
MBX-8025
Code English
seladelpar [INN]
Common Name English
ACETIC ACID, 2-(4-(((2R)-2-ETHOXY-3-(4-(TRIFLUOROMETHYL)PHENOXY)PROPYL)THIO)-2-METHYLPHENOXY)-
Systematic Name English
SELADELPAR [USAN]
Common Name English
Seladelpar [WHO-DD]
Common Name English
(4-(((2R)-2-ETHOXY-3-(4-(TRIFLUOROMETHYL)PHENOXY)PROPYL)SULFANYL)-2-METHYLPHENOXY)ACETIC ACID PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR (PPAR) AGONIST,ANTIHYPERLIPIDAEMIC
Common Name English
((4-(((2R)-2-ETHOXY-3-(4-(TRIFLUOROMETHYL)PHENOXY)PROPYL)THIO)-2-METHYLPHENYL)OXY)ACETIC ACID
Systematic Name English
RWJ-800025
Code English
ACETIC ACID, (4-(((2R)-2-ETHOXY-3-(4-(TRIFLUOROMETHYL)PHENOXY)PROPYL)THIO)-2-METHYLPHENOXY)-
Systematic Name English
ACETIC ACID, (4-(((2R)-2-ETHOXY-3-(4-(TRIFLUOROMETHYL)PHENOXY)PROPYL)THIO)-2-METHYLPHENOXY)- ((4-(((2R)-2-ETHOXY-3-(4-(TRIFLUOROMETHYL)PHENOXY)PROPYL)THIO)-2-METHYLPHENYL)OXY)ACETIC ACID
Systematic Name English
(R)-2-(4-((2-ETHOXY-3-(4-(TRIFLUOROMETHYL)PHENOXY)PROPYL)-THIO)-2-METHYLPHENOXY)ACETIC ACID
Systematic Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/17/1930
Created by admin on Mon Mar 31 18:10:52 GMT 2025 , Edited by admin on Mon Mar 31 18:10:52 GMT 2025
Code System Code Type Description
WIKIPEDIA
Seladelpar
Created by admin on Mon Mar 31 18:10:52 GMT 2025 , Edited by admin on Mon Mar 31 18:10:52 GMT 2025
PRIMARY
NCI_THESAURUS
C167015
Created by admin on Mon Mar 31 18:10:52 GMT 2025 , Edited by admin on Mon Mar 31 18:10:52 GMT 2025
PRIMARY
ChEMBL
CHEMBL3545019
Created by admin on Mon Mar 31 18:10:52 GMT 2025 , Edited by admin on Mon Mar 31 18:10:52 GMT 2025
PRIMARY
SMS_ID
100000177208
Created by admin on Mon Mar 31 18:10:52 GMT 2025 , Edited by admin on Mon Mar 31 18:10:52 GMT 2025
PRIMARY
EPA CompTox
DTXSID001045332
Created by admin on Mon Mar 31 18:10:52 GMT 2025 , Edited by admin on Mon Mar 31 18:10:52 GMT 2025
PRIMARY
USAN
EF-45
Created by admin on Mon Mar 31 18:10:52 GMT 2025 , Edited by admin on Mon Mar 31 18:10:52 GMT 2025
PRIMARY
FDA UNII
7C00L34NB9
Created by admin on Mon Mar 31 18:10:52 GMT 2025 , Edited by admin on Mon Mar 31 18:10:52 GMT 2025
PRIMARY
CAS
851528-79-5
Created by admin on Mon Mar 31 18:10:52 GMT 2025 , Edited by admin on Mon Mar 31 18:10:52 GMT 2025
PRIMARY
INN
10340
Created by admin on Mon Mar 31 18:10:52 GMT 2025 , Edited by admin on Mon Mar 31 18:10:52 GMT 2025
PRIMARY
DRUG BANK
DB12390
Created by admin on Mon Mar 31 18:10:52 GMT 2025 , Edited by admin on Mon Mar 31 18:10:52 GMT 2025
PRIMARY
PUBCHEM
11236126
Created by admin on Mon Mar 31 18:10:52 GMT 2025 , Edited by admin on Mon Mar 31 18:10:52 GMT 2025
PRIMARY
Related Record Type Details
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA
TARGET->WEAK AGONIST
EC50
CYTOCHROME P450 2C9
METABOLIC ENZYME -> SUBSTRATE
Structure of SELADELPAR LYSINE
SALT/SOLVATE -> PARENT
Structure of SELADELPAR LYSINE ANHYDROUS
SALT/SOLVATE -> PARENT
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA
TARGET -> AGONIST
SELECTIVE
EC50
Structure of SELADELPAR LYSINE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of SELADELPAR
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966